BackgroundThe one-strength injection regimen has increasingly become the mainstream paradigm for subcutaneous immunotherapy (SCIT). This study aimed to assess the safety and tolerability of an optimal accelerated scheme for SCIT using a house dust mite…
BackgroundDuring the COVID-19 pandemic, adenoviral vector-based Sputnik V vaccine was used to vaccinate the civilian population of 74 countries worldwide. As part of laboratory monitoring of the effectiveness of the Sputnik V vaccine, a decrease in eff…
IntroductionCOVID-19 boosters restore waning immunity. After demonstrating non-inferiority of 15 μg versus 30 μg BNT162b2 at 28 days in Mongolian adults, we assessed 24-month immunogenicity and safety.MethodsIn this randomised, controlled trial, adults…
PurposeThe purpose of this study was to prospectively evaluate the clinical efficacy and safety of baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, in the treatment of patients with Vogt–Koyanagi–Harada (VKH) disease.DesignThe study was des…
IntroductionCancer-related pain remains a critical clinical challenge, with existing opioid-based therapies often yielding inadequate relief and significant side effects. This study investigates the therapeutic potential of JK5G postbiotics—a formulati…
ObjectivesIn sepsis, circulating cell-free DNA (cfDNA) originates from host cells (damage-associated molecular patterns, DAMPs) and pathogens (pathogen-associated molecular patterns, PAMPs), contributing to immune activation and offering potential as b…
BackgroundAnti-CD19 chimeric antigen receptor (CAR)-T cell therapy has demonstrated clinical potential in treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, enhancing its therapeutic efficacy remains a significant cha…
Background and aimPOLB 001 is an oral p38 mitogen-activated protein kinase (MAPK) inhibitor in development for the prevention of cancer immunotherapy-induced cytokine release syndrome (CRS). It has previously been shown to be well tolerated and capable…
ObjectiveSMET12 is a bispecific T-cell engager targeting epidermal growth factor receptor (EGFR) and CD3. This phase 2 clinical trial aimed to investigate the efficacy and safety of SMET12 plus toripalimab and chemotherapy among advanced non-small-cell…
IntroductionLong COVID (LC) is an infection-associated chronic condition and illness (IACCI) with no currently approved treatments. In order to address SARS-CoV-2 persistence and herpesvirus reactivation, which have been implicated as drivers of LC, su…
